Johnson & Johnson (JNJ) Financial Statements
Historical financial data — 40 statements covering FY2016–FY2025
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divest...
Johnson & Johnson's revenue increased 6.0% year over year, from $88.82B to $94.19B.
Net income increased 90.6% over the same period, from $14.07B to $26.80B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 31% in total.
Total debt increased by 30.8% to $47.93B.
The debt-to-equity ratio stands at 0.59, indicating a moderate leverage profile.
Operating cash flow grew 1.1% to $24.53B.
Johnson & Johnson maintains a strong net profit margin of 28.5%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2023 | $50.28B+103.2% | $5.08B | $33.67B | $6.03B | $7.44B | $191.69B | $45.60B | $75.15B |
| Q3 FY2023 | $63.76B+26.8% | $31.10B | $44.01B | $10.24B | $14.93B | $166.06B | $29.92B | $71.23B |
| Q1 FY2024 | $21.38B-66.5% | $3.25B | $14.87B | $3.71B | $3.66B | $171.97B | $33.63B | $70.02B |
| Q3 FY2024 | $66.30B+210.1% | $10.63B | $45.96B | $12.80B | $17.28B | $178.29B | $35.75B | $70.16B |
| Q1 FY2025 | $21.89B-67.0% | $11.00B | $14.54B | $13.63B | $4.17B | $193.67B | $52.25B | $78.11B |
| Q2 FY2025 | $45.64B+108.5% | $16.54B | $30.65B | $20.12B | $8.05B | $193.39B | $50.76B | $78.47B |
| Q3 FY2025 | $69.63B+52.6% | $21.69B | $47.34B | $27.61B | $17.22B | $192.82B | $45.80B | $79.28B |
| Q1 FY2026 | $24.06B-65.4% | $5.24B | $15.96B | $5.99B | $2.51B | $200.89B | $54.99B | $81.19B |
Balance Sheet Summary (Latest Period)
Total Assets
$199.21B
Total Liabilities
$117.67B
Total Equity
$81.54B
Cash & Equivalents
$20.10B
Total Debt
$47.93B
Current Assets
$55.62B
Current Liabilities
$54.13B
Retained Earnings
$168.98B